Synthesis of Four Heterocyclic Drug Molecules Repurposed for COVID-19

(E-pub Ahead of Print)

Author(s): Geetanjali, Richa Srivastava, Ram Singh*

Journal Name: Mini-Reviews in Organic Chemistry


Become EABM
Become Reviewer
Call for Editor

Abstract:

The research on the disease COVID-19 is an ongoing process since its outbreak as a pandemic. The repurposing of existing approved drugs has received priority attention due to some promising results obtained regarding COVID-19. In this article, some of the important chemical methodologies adopted for the synthesis of umifenovir, (s)-cidofovir, ribavirin, and ruxolitinib have been discussed. The repurposing of these approved drugs has received priority attention due to some promising results obtained regarding COVID-19 and some drugs are under more therapeutic trials. This manuscript has highlighted the synthetic strategies of four heterocyclic-based approved drugs, umifenovir, (s)-cidofovir, ribavirin, and ruxolitinib, repurposed for the treatment of COVID-19.

Keywords: COVID-19, repurposed drugs, synthesis, umifenovir, (s)-cidofovir, ribavirin, ruxolitinib.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 25 March, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1570193X18666210325121225
Price: $95

Article Metrics

PDF: 199